Emerging biological roles for erythropoietin in the nervous system
The DOI matches its Crossref record; 107 of the 108 references it cites were found in a registry or an index.
Abstract
Erythropoietin mediates an evolutionarily conserved, ancient immune response that limits damage to the heart, the nervous system and other tissues following injury. New evidence indicates that erythropoietin specifically prevents the destruction of viable tissue surrounding the site of an injury by signalling through a non-haematopoietic receptor. Engineered derivatives of erythropoietin that have a high affinity for this receptor have been developed, and these show robust tissue-protective effects in diverse preclinical models without stimulating erythropoiesis. A recent successful proof-of-concept clinical trial that used erythropoietin to treat human patients who had suffered a stroke encourages the evaluation of both this cytokine and non-erythropoietic derivatives as therapeutic agents to limit tissue injury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Erythropoietin was originally recognized via its role in erythropoiesis [2145-2147] (hence its name, of course), but it has become evident that it has many other roles, and in particular it is observed phenomenologically that erythropoietin (and non-erthyropoetic derivatives) is protective in a number of inflammatory conditions that accompany many diseases such as those listed above [940,942,2148-”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [2150]
Citations
Cites
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
Brines, M. L., Ghezzi, P., Keenan, S., Agnello, D., de Lanerolle, N. C., Cerami, C., Itri, L. M., & Cerami, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.19.10526 · Cited by 1,402 · cited 1×
“Follow-up studies confirmed erythropoietin to be a neuroprotective factor in hypoxic-ischaemic, traumatic, excitotoxic and inflammatory injurie”
BackgroundSelf-citationHIF-1 and mechanisms of hypoxia sensing
Semenza, G. L. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00194-0 · Cited by 1,268
Henke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K.-D., Schilcher, B., Mose, S., Beer, K. T., Burger, U., Dougherty, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14567-9 · Cited by 1,250 · cited 1×
“It is worrying that some cancer patients treated with rhEPO have also shown tumour expansio”
BackgroundErythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
Ehrenreich, H., Hasselblatt, M., Dembowski, C., Cepek, L., Lewczuk, P., Stiefel, M., Rustenbeck, H.-H., Breiter, N., Jacob, S., Knerlich, F., et al. (2002) · Molecular Medicine · doi:10.1007/bf03402029 · Cited by 1,028
Self-citationJuhaszova, M., Zorov, D. B., Kim, S.-H., Pepe, S., Fu, Q., Fishbein, K. W., Ziman, B. D., Wang, S., Ytrehus, K., Antos, C. L., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19906 · Cited by 1,026
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
Sirén, A.-L., Fratelli, M., Brines, M., Goemans, C., Casagrande, S., Lewczuk, P., Keenan, S., Gleiter, C., Pasquali, C., Capobianco, A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051606598 · Cited by 1,019
Self-citationIn vivo evidence that erythropoietin protects neurons from ischemic damage
Sakanaka, M., Wen, T.-C., Matsuda, S., Masuda, S., Morishita, E., Nagao, M., & Sasaki, R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4635 · Cited by 949 · cited 1×
“Follow-up studies confirmed erythropoietin to be a neuroprotective factor in hypoxic-ischaemic, traumatic, excitotoxic and inflammatory injurie”
BackgroundDigicaylioglu, M., & Lipton, S. A. (2001) · Nature · doi:10.1038/35088074 · Cited by 923 · cited 1×
“Furthermore, although it has been reported that STAT is part of erythropoietin's neuroprotective signalling cascade in vitro , in vivo studies largely have not supported the involvement of STATs in erythropoietin cytoprotectio”
BackgroundPurification of human erythropoietin.
Miyake, T., Kung, C. K., & Goldwasser, E. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)63387-9 · Cited by 886
Derivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic
Leist, M., Ghezzi, P., Grasso, G., Bianchi, R., Villa, P., Fratelli, M., Savino, C., Bianchi, M., Nielsen, J., Gerwien, J., et al. (2004) · Science · doi:10.1126/science.1098313 · Cited by 803
Self-citation
Cited by
Items 201–300 of 527
Erythropoietin and Normal Brain Development: Receptor Expression Determines Multi-Tissue Response
Chen, Z., Warin, R., & Noguchi, C. T. (2006) · Neurodegenerative Diseases · doi:10.1159/000092096 · Cited by 36
Erythropoietin: Recent Developments in the Treatment of Spinal Cord Injury
Carelli, S., Marfia, G., Giulio, A. M. D., Ghilardi, G., & Gorio, A. (2011) · Neurology Research International · doi:10.1155/2011/453179 · Cited by 38
Age-Related Hearing Loss and Its Cellular and Molecular Bases
Ohlemiller, K. K., & Frisina, R. D. (2008) · Springer eBooks · doi:10.1007/978-0-387-72561-1_6 · Cited by 35
Luo, B., Jiang, M., Yang, X., Zhang, Z., Xiong, J., Schluesener, H. J., Zhang, Z., & Wu, Y. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.04.015 · Cited by 36
Liu, Y., Luo, B., Han, F., Li, X., Xiong, J., Jiang, M., Yang, X., Wu, Y., & Zhang, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090942 · Cited by 36
Szabadfi, K., Pintér, E., Reglődi, D., & Gabriel, R. (2014) · International review of cytology · doi:10.1016/b978-0-12-800179-0.00001-5 · Cited by 44
Bouzat, P., Francony, G., Thomas, S., Valable, S., Mauconduit, F., Fevre, M.-C., Barbier, E., Bernaudin, M., Lahrech, H., & Payen, J. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e31821cb7b2 · Cited by 35
Erythropoietin in diabetic retinopathy
Reid, G. A., & Lois, N. (2017) · Vision Research · doi:10.1016/j.visres.2017.05.010 · Cited by 34
Tayra, J. T., Kameda, M., Yasuhara, T., Agari, T., Kadota, T., Wang, F., Kikuchi, Y., Liang, H., Shinko, A., Wakamori, T., et al. (2013) · Brain Research · doi:10.1016/j.brainres.2013.01.042 · Cited by 34
Pankratova, S., Gu, B., Kiryushko, D. V., Korshunova, I., Køhler, L. B., Rathje, M., Bock, E., & Berezin, V. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07751.x · Cited by 34
EPO attenuates inflammatory cytokines by Muller cells in diabetic retinopathy
Xu, G. (2010) · Frontiers in Bioscience-Elite · doi:10.2741/e234 · Cited by 34
Erythropoietin exerts cell protective effect by activating PI3K/Akt and MAPK pathways in C6 Cells
Kwon, M., Kim, M., Kim, S., Park, K.-D., Yoo, S. H., Oh, I.-U., Pak, S., & Seo, Y.-J. (2013) · Neurological Research · doi:10.1179/1743132813y.0000000284 · Cited by 33
Schmidt, R. E., Feng, D., Wang, Q., Green, K. G., Snipes, L. L., Yamin, M., & Brines, M. L. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.05.025 · Cited by 35
Self-citationHahn, N., Knorr, D. Y., Liebig, J., Wüstefeld, L., Peters, K., Buescher, M., Bucher, G., Ehrenreich, H., & Heinrich, R. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00223 · Cited by 34
Konstantinopoulos, P. A., Karamouzis, M. V., & Papavassiliou, A. G. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.07.002 · Cited by 34
Zhang, G., Lehmann, H. C., Богданова, Н. А., Gao, T., Zhang, J., & Sheikh, K. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027067 · Cited by 36
Erythropoietin Protects against Murine Cerebral Malaria through Actions on Host Cellular Immunity
Xu, W., Li, Y., Sun, X., Zhu, X., Feng, Y., Liu, J., Jiang, Y., Shang, H., Cui, L., & Cao, Y. (2013) · Infection and Immunity · doi:10.1128/iai.00929-13 · Cited by 33
Sathyanesan, M., Watt, M. J., Haiar, J. M., Scholl, J. L., Davies, S. R., Paulsen, R. T., Wiederin, J. L., Ciborowski, P. S., & Newton, S. S. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0168-9 · Cited by 33
Erythropoietin and cerebral vascular protection: role of nitric oxide
Santhanam, A. V. R., & Katušić, Z. S. (2006) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2006.00441.x · Cited by 32
Anti‐Inflammatory Effect of Erythropoietin in the TNBS ‐induced Colitis
Mateus, V., Rocha, J. P., Alves, P., Mota‐Filipe, H., Sepodes, B. M. N., & Pinto, R. M. A. (2016) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12663 · Cited by 31
Hou, J., Klippel, K., & Bose, P. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl38904 · Cited by 35
Impact of bacterial infections on erythropoiesis
de Souza, L. V., Hoffmann, A., & Weiß, G. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1841636 · Cited by 32
Coimbra-Costa, D., Garzón, F., Alva, N., Pinto, T. C. C., Aguado, F., Torrella, J. R., Carbonell, T., & Rama, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105272 · Cited by 33
Erythropoietin improves spatial learning and memory in streptozotocin model of dementia
Hamidi, G. A., Arabpour, Z., Shabrang, M., Rashidi, B., Alaei, H., Sharifi, M. R., Salami, M., & Reisi, P. (2013) · Pathophysiology · doi:10.1016/j.pathophys.2013.01.001 · Cited by 30
Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects
Gokhale, M., Vainstein, V., Tom, J., Thomas, S., Lawrence, C. E., Gluzman‐Poltorak, Z., Siebers, N., & Basile, L. A. (2014) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-3-11 · Cited by 30
Neuroprotection and CD131/GDNF/AKT Pathway of Carbamylated Erythropoietin in Hypoxic Neurons
Ding, J., Wang, J., Li, Q., Yu, J., Ma, C., Wang, X., Lü, C., & Xiao, B. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0022-0 · Cited by 30
Erythropoietin and progression of CKD
Bahlmann, F. H., Kielstein, J. T., Haller, H. G., & Fliser, D. (2007) · Kidney International · doi:10.1038/sj.ki.5002484 · Cited by 30
Robinson, S., Winer, J. L., Chan, L. A. S., Oppong, A. Y., Yellowhair, T. R., Maxwell, J. R., Andrews, N. A., Yang, Y., Sillerud, L. O., Meehan, W. P., III, et al. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00451 · Cited by 29
“Prior data indicate that EPO crosses the blood-brain barrier via non-receptor mediated transport in both humans and rodents (10, 24).”
BackgroundCervellini, I., Bello, E., Frapolli, R., Porretta‐Serapiglia, C., Oggioni, N., Canta, A., Lombardi, R., Camozzi, F., Roglio, I., Melcangi, R. C., et al. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9127-9 · Cited by 29
Yang, Y., Zhang, J., Liu, H., Wang, J., Xin, J., & Deng, M. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1158-1 · Cited by 29
HSV-Mediated Delivery of Erythropoietin Restores Dopaminergic Function in MPTP-Treated Mice
Puskovic, V., Wolfe, D. P., Wechuck, J., Krisky, D. M., Collins, J. M., Glorioso, J. C., Fink, D. J., & Mata, M. M. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.07.004 · Cited by 29
“There is substantial evidence for a neuroprotective role of EPO [17] and specific evidence that EPO can be used to protect DA neurons from MPTP [11] or 6-OHDA [12].”
BackgroundKaur, D., Behl, T., Sehgal, A., Singh, S., Sharma, N., Badavath, V. N., Hassan, S. S. U., Hasan, M. M., Bhatia, S., Al-Harassi, A., et al. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00820-6 · Cited by 28
Erythropoietin and co.: intrinsic structure and functional disorder
Uversky, V. N., & Redwan, E. M. M. M. (2016) · Molecular BioSystems · doi:10.1039/c6mb00657d · Cited by 30
Neuroprotective effect of a new variant of Epo nonhematopoietic against oxidative stress
Castillo, C., Zaror, S., Gonzalez, M., Hidalgo-Gajardo, A., Burgos, C. F., Cabezas, O. I., Hugues, F., Jiménez, S. P., Gonzalez-Horta, E. E., González‐Chavarría, I., et al. (2017) · Redox Biology · doi:10.1016/j.redox.2017.09.010 · Cited by 31
Non‐erythropoietic erythropoietin‐derived peptide protects mice from systemic lupus erythematosus
Huang, B., Jiang, J., Luo, B., Zhu, W., Liu, Y., Wang, Z., & Zhang, Z. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13608 · Cited by 28
Poulsen, T. D., Andersen, L. W., Steinbrüchel, D. A., Goetze, J. P., Jørgensen, O. S., & Olsen, N. V. (2009) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2008.08.018 · Cited by 28
Giese, A., Frahm, J., Hübner, R., Luo, J., Wree, A., Frech, M. J., Rolfs, A., & Ortinau, S. (2010) · BMC Cell Biology · doi:10.1186/1471-2121-11-94 · Cited by 28
A double-edged sword: Erythropoietin eyed in retinopathy of prematurity
Chen, J., & Smith, L. E. H. (2008) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2008.02.001 · Cited by 28
Liu, L., Liu, C., HOU, L., Lv, J., WU, F., Yang, X., Ren, S., Ji, W., WANG, M., & Chen, L. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4426 · Cited by 28
Targeting Water in the Brain: Role of Aquaporin-4 in Ischemic Brain Edema
Mamtilahun, M., Tang, G., Zhang, Z., Wang, Y., Tang, Y., & Yang, G. (2019) · Current Drug Targets · doi:10.2174/1389450120666190214115309 · Cited by 27
Hahn, N., Büschgens, L., Schwedhelm‐Domeyer, N., Bank-Aubin, S., Geurten, B. R. H., Neugebauer, P., Massih, B., Göpfert, M. C., & Heinrich, R. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00251 · Cited by 30
Vascular Endothelial Growth Factor and Other Angioglioneurins
Lafuente, J. V., Ortuzar, N., Bengoetxea, H., Bulnes, S., & Argandoña, E. (2012) · International review of neurobiology · doi:10.1016/b978-0-12-386986-9.00012-0 · Cited by 32
Oxygen Sensing: A Common Crossroad in Cancer and Neurodegeneration
Quaegebeur, A., & Carmeliet, P. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_83 · Cited by 33
“2009) and erythropoietin (Brines and Cerami 2005), HIF-1a is arguably pinpointed as moderator of neuroprotection.”
BackgroundAndreeva, N., Amarjargal, N., Haupt, H., Gross, J., & Mazurek, B. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.11.013 · Cited by 27
Toba, H., Nakashima, K., Oshima, Y., Kojima, Y., Tojo, C., Nakano, A., Wang, J., Kobara, M., & Nakata, T. (2010) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2010.05445.x · Cited by 28
From neurogenesis to neuroprotection in the epilepsy: signalling by erythropoietin
Castañeda‐Arellano, R., Beas-Zarate, C., Feria-Velasco, A. I., Bitar-Alatorre, E. W., & Rivera-Cervantes, M. C. (2014) · Frontiers in bioscience · doi:10.2741/4295 · Cited by 27
The Use of Erythropoietin and its Derivatives to Treat Spinal Cord Injury
Mofidi, A., Bader, A., & Pavlica, S. (2011) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955711796355267 · Cited by 26
Bench to bedside: A role for erythropoietin in sepsis
Walden, A. P., Young, D., & Sharples, E. J. (2010) · Critical Care · doi:10.1186/cc9049 · Cited by 29
Erythropoietin for oncology supportive care
McKinney, M. S., & Arcasoy, M. O. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.03.003 · Cited by 25
Ehrenreich, H., Garcia‐Agudo, L. F., Steixner-Kumar, A. A., Wilke, J. B. H., & Butt, U. J. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01551-5 · Cited by 28
Developing drug strategies for the neuroprotective treatment of acute ischemic stroke
Tuttolomondo, A., Pecoraro, R., Arnao, V., Maugeri, R., Iacopino, D. G., & Pinto, A. V. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1101345 · Cited by 25
Diederich, K., Schäbitz, W., & Minnerup, J. (2010) · Hippocampus · doi:10.1002/hipo.20904 · Cited by 26
Lymphoma, Erythrocytosis, and Tumor Erythropoietin Gene Expression in a Horse
Koch, T. G., Wen, X., & Bienzle, D. (2006) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2006.tb00734.x · Cited by 25
Robach, P., Recalcati, S., Girelli, D., Campostrini, N., Kempf, T., Wollert, K. C., Corbella, M., Santambrogio, P., Perbellini, L., Brasse‐Lagnel, C., et al. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12122 · Cited by 25
Dmytriyeva, O., Belmeguenaï, A., Bezin, L., Soud, K., Woldbye, D. P. D., Gøtzsche, C. R., & Pankratova, S. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.05.003 · Cited by 25
Intranasal erythropoietin therapy in nervous system disorders
Genç, Ş., Zadeoğluları, Z., Öner, M. G., Genç, K., & Digicaylioglu, M. H. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.540236 · Cited by 27
Expression of erythropoietin and its receptor in neuroblastomas
Sartelet, H., Fabrè, M., Castaing, M., Bosq, J., Racu, I., Lagonotte, E., Scott, V., Lécluse, Y., Barette, S., Michiels, S., et al. (2007) · Cancer · doi:10.1002/cncr.22879 · Cited by 24
Peterson, T. E., & Katušić, Z. S. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707162 · Cited by 24
Carelli, S., Giallongo, T., Gombalová, Z. T., Rey, F., Gorio, M. C., Mazza, M., & Giulio, A. M. D. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1375-2 · Cited by 25
“EPO’s neuroprotective and anti-inflammatory effects are very well studied and widely supported in the literature [72].”
BackgroundErythropoietin augments the cytokine response to acute endotoxin-induced inflammation in humans
Højman, P., Taudorf, S., Lundby, C., & Pedersen, B. K. (2009) · Cytokine · doi:10.1016/j.cyto.2008.12.005 · Cited by 23
“In cerebral ischemia, rHuEPO exerts similar protective effects by showing neurotrophic, anti-inflammatory and anti-oxidant actions [5].”
BackgroundLimiting spinal cord injury by pharmacological intervention
Priestley, J. V., Michael-Titus, A. T., & Tetzlaff, W. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52137-8.00029-2 · Cited by 30
“…(EPO) and its receptors are present in the central and peripheral nervous systems, and the cytokine has been shown to induce significant neuroprotection in a variety of conditions, including peripheral nerve injury, stroke, and multiple sclerosis, and also SCI (Brines and Cerami, 2005).”
Inkster, B., Zai, G. C., Lewis, G., & Miskowiak, K. W. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0270-z · Cited by 27
Vinberg, M., Miskowiak, K. W., Højman, P., Pedersen, M., & Kessing, L. V. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127629 · Cited by 23
Srisawat, N., Manotham, K., Eiam‐Ong, S., Katavetin, P., Praditpornsilpa, K., & Eiam‐Ong, S. (2008) · International Journal of Urology · doi:10.1111/j.1442-2042.2008.02149.x · Cited by 23
EV-3, an endogenous human erythropoietin isoform with distinct functional relevance
Bonnas, C., Wüstefeld, L., Winkler, D., Kronstein‐Wiedemann, R., Dere, E., Specht, K., Boxberg, M., Tonn, T., Ehrenreich, H., Stadler, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-03167-0 · Cited by 23
Reddy, M. K., Vasir, J. K., Hegde, G. V., Joshi, S. S., & Labhasetwar, V. D. (2007) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248406297326 · Cited by 23
“In addition, several studies have demonstrated its antiapoptotic and anti-inflammatory, angiogenic, and neuroprotective properties, especially in ischemic conditions.(22,28) With growing evidence of protective role of EPO in several disease conditions, we speculated that EPO 242 Journal of Cardiovascular Pharmacology…”
BackgroundDmytriyeva, O., Pankratova, S., Korshunova, I., & Walmod, P. S. (2016) · Mediators of Inflammation · doi:10.1155/2016/1346390 · Cited by 22
Aghaei, I., Nazeri, M., Shabani, M., Mossavinasab, M., Mirhosseini, F., Nayebpour, M., & Dalili, A. (2014) · Metabolic Brain Disease · doi:10.1007/s11011-014-9600-x · Cited by 22
“This may imply that ERYprotects neurons from other pathways (Brines and Cerami 2005).”
BackgroundInfluentialSanthanam, A. V. R., d’Uscio, L. V., & Katušić, Z. S. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12824 · Cited by 22
Imamura, R., Isaka, Y., Sandoval, R. M., Ichimaru, N., Abe, T., Okumi, M., Yazawa, K., Kitamura, H., Kaimori, J., Nonomura, N., et al. (2012) · Clinical and Experimental Nephrology · doi:10.1007/s10157-012-0647-x · Cited by 22
Carbamoylated erythropoietin induces a neurotrophic gene profile in neuronal cells
Tiwari, N. K., Sathyanesan, M., Schweinle, W. E., & Newton, S. S. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.07.011 · Cited by 22
“Progress in understanding EPO's biological actions over the past two decades has shown that it has robust neurotrophic and neuroprotective actions on the brain (Brines and Cerami, 2005).”
Garcia‐Agudo, L. F., Steixner-Kumar, A. A., Curto, Y., Barnkothe, N., Hassouna, I. A., Jähne, S., Butt, U. J., Grewe, K., Weber, M. S., Green, K., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109548 · Cited by 25
“Importantly, these EPO-mediated adaptation processes likely also involve other brain cell types that express and/or bind EPO, at least in disease models (Brines and Cerami, 2005; Ott et al., 2015; Sargin et al., 2010; Sirén et al., 2009).”
BackgroundHypoxia-induced mediators and neurologic disease
Benarroch, E. E. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b2a719 · Cited by 24
Siddiqui, M. R., Attar, F., Mohanty, V., Kim, K. S., Mayanil, C. S. K., & Tomita, T. (2018) · Child s Nervous System · doi:10.1007/s00381-018-3865-z · Cited by 22
Second-generation non-hematopoietic erythropoietin-derived peptide for neuroprotection
Cho, B., Yoo, S., Kim, S. Y., Lee, C., Lee, Y., Lee, S., & Moon, C. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102223 · Cited by 21
High dose erythropoietin promotes functional recovery of rats following facial nerve crush
Zhang, W., Sun, B., Yu, Z., An, J., Liu, Q., & Ren, T. (2009) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2008.06.013 · Cited by 21
Sasaki, N., Sekiguchi, M., Kikuchi, S., & Konno, S. (2011) · Spine · doi:10.1097/brs.0b013e3181f137a8 · Cited by 21
Carelli, S., Giallongo, T., Viaggi, C., Latorre, E., Gombalová, Z. T., Raspa, A., Mazza, M., Vaglini, F., Giulio, A. M. D., & Gorio, A. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.03.035 · Cited by 22
Moosavi, M., Hooshmandi, E., Javadpour, P., Maghsoudi, N., Katinger, H. W. D., & Ghasemi, R. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112554 · Cited by 22
Hamano, Y., Aoki, T., Shirai, R., Hatano, M., Kimura, R., Ogawa, M., Yokosuka, O., & Ueda, S. (2009) · Nephron Experimental Nephrology · doi:10.1159/000256569 · Cited by 21
Erythropoietin in cardiac disease: New features of an old drug
Ruifrok, W.-P. T., de Boer, R. A., Westenbrink, B. D., van Veldhuisen, D. J., & van Gilst, W. H. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.01.054 · Cited by 23
Erythropoietin Attenuates Post-Traumatic Injury in Organotypic Hippocampal Slices
Adembri, C., Bechi, A., Meli, E., Gramigni, E., Venturi, L., Moroni, F., Gaudio, A. R. D., & Pellegrini-Giampietro, D. E. (2004) · Journal of Neurotrauma · doi:10.1089/0897715041651079 · Cited by 21
Ehrenreich, H., Gassmann, M., Poustka, L., Burtscher, M., Hammermann, P., Sirén, A., Nave, K., & Miskowiak, K. W. (2023) · Neuroprotection/Neuroprotection (Chichester, England. Print) · doi:10.1002/nep3.15 · Cited by 26
Li, W., Lv, W., Xu, X., Jiang, H., & Bang, O. (2015) · Neural Regeneration Research · doi:10.4103/1673-5374.162759 · Cited by 20
Merchionne, F., & Dammacco, F. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07702.x · Cited by 22
Erythropoietin for the Treatment of Subarachnoid Hemorrhage: A Review
Turner, J. D., Mammis, A., & Prestigiacomo, C. J. (2010) · World Neurosurgery · doi:10.1016/j.wneu.2010.02.026 · Cited by 20
“It has been sugested that unlike the homodimeric version f the receptor in erythroid cells, EPOR in he brain functions as a heteroreceptor omposed of a single EPOR subunit and an ssociated -chain ( CR) subunit (13, 56).”
BackgroundInfluentialNeurocognitive Dysfunctions in Iron Deficiency Patients
Zhukovskaya, E. V., Karelin, A. F., & Rumyantsev, A. G. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82620 · Cited by 20
Treating patients with schizophrenia deficit with erythropoietin?
Fond, G. B., Macgregor, A., Attal, J., Larue, A., Brittner, M., Ducasse, D., & Capdevielle, D. (2012) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2012.02359.x · Cited by 19
Pretreatment with erythropoietin reduces hepatic ischemia-reperfusion injury.
Luo, Y.-H., Li, Z., Liu, L., & Dong, G.-H. (2009) · Hepatobiliary & pancreatic diseases international · Cited by 19
Toba, H., Morishita, M., Tojo, C., Nakano, A., Oshima, Y., Kojima, Y., Yoshida, M., Nakashima, K., Wang, J., Kobara, M., et al. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.01.043 · Cited by 19
Merelli, A., Caltana, L. R., Lazarowski, A., & Brusco, A. (2011) · Drug metabolism and drug interactions · doi:10.1515/dmdi.2011.007 · Cited by 20
Cubo, E., González, M., del Puerto, I., de Yébenes, J. G., Fernández-Arconada, O., y Galán, J. M. T. G., & on behalf of the European Huntington's Disease Initiative Study Group (2011) · Movement Disorders · doi:10.1002/mds.24062 · Cited by 19
Begemann, M., Groß, O., Wincewicz, D., Hardeland, R., Gastaldi, V. D., Vieta, E., Weißenborn, K., Miskowiak, K. W., Moerer, O., & Ehrenreich, H. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00381-5 · Cited by 18
Creangă, E.-C., Stan, R., Nicolae, A. C., Drăgoi, C. M., & Dumitrescu, I.-B. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091190 · Cited by 19
“In the central nervous system, EPO modulates neuroinflammation, prevents apoptosis, and enhances neurogenesis [34].”
Goetghebeur, P., Lerdrup, L., Sylvest, A., & Dias, R. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1990-9 · Cited by 19
Wang, L., Li, H., Wen, J., Peng, T., Zeng, H., & Wang, L.-Y. (2014) · Tumori Journal · doi:10.1177/1578.17216 · Cited by 18
Is there a role for erythropoietin in cardiovascular disease?
Vogiatzi, G., Briasoulis, Α., Tousoulis, D., Παπαγεωργίου, Ν., & Stefanadis, C. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903547819 · Cited by 18
Intermittent Hypobaric Hypoxia Induces Neuroprotection in Kainate-Induced Oxidative Stress in Rats
Coimbra-Costa, D., Alva, N., Motos, L. T., Gámez, A., Carbonell, T., & Rama, R. (2013) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9945-8 · Cited by 20
Neuroprotection and endocytosis: erythropoietin receptors in insect nervous systems
Miljus, N., Massih, B., Weis, M. A., Rison, J. V., Bonnas, C., Sillaber, I., Ehrenreich, H., Geurten, B. R. H., & Heinrich, R. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.13967 · Cited by 19
Cell Type Specific Signalling by Hematopoietic Growth Factors in Neural Cells
Byts, N., Samoylenko, A., Woldt, H., Ehrenreich, H., & Sirén, A. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9149-0 · Cited by 19
Metadata
- Authors
- Brines, M., & Cerami, A.
- Corresponding author
- Brines, Michael
- Venue
- Nature Reviews Neuroscience
- Published
- 2005-06-01
- Volume
- 6
- Issue
- 6
- Pages
- 484-494
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W2168867226
- Cited by
- 523
- References
- 108
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 6 · 2023: 8 · 2022: 18 · 2021: 21 · 2020: 13 · 2019: 25 · 2018: 17 · 2017: 16 · 2016: 21 · 2015: 19 · 2014: 22 · 2013: 30 · 2012: 38
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Update notices
- correction (2005-08-01)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- www.springer.com/tdm (unspecified)
- Locations
- Nature reviews. Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heme Oxygenase-1 and Carbon Monoxide
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Keywords
- erythropoietin, nervous system, neuroprotection, tissue damage, stroke, neuroinflammation
- MeSH terms
- Animals, Central Nervous System, Erythropoietin, Humans, Signal Transduction, Receptors, Cytokine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.